Regular Article
A Proposal of a Pharmacokinetic/pharmacodynamic (PK/PD) Index Map for Selecting an Optimal PK/PD Index from Conventional Indices (AUC/MIC, Cmax/MIC, and TAM) for Antibiotics

https://doi.org/10.2133/dmpk.DMPK-14-RG-013Get rights and content

Summary:

A pharmacokinetic/pharmacodynamic (PK/PD) analysis is important in antibiotic chemotherapy. Basically, the in vivo efficacy of antibiotics that exert concentration-dependent effects can be predicted using conventional PK/PD indices such as the ratio of the area under the curve to the minimum inhibitory concentration (AUC/MIC) and/or the ratio of the maximum plasma concentration to MIC (Cmax/MIC), whereas that of antibiotics with time-dependent effects can be determined using the period of time for which the drug concentration exceeds the MIC (time above MIC [TAM]). However, an optimal PK/PD index remains to be established for some antibiotics. Thus, a PK/PD model which describes the PK profile and effect of an antibiotic was developed, and the results obtained from this model were interpreted to form a PK/PD index map to assess the optimal PK/PD index for the antibiotic. The findings from the map were generally consistent with clinical outcomes even for the antibiotics which proved to be exceptions to the conventional classification. For example, AUC/MIC was an optimal index for azithromycin despite its time-dependent bactericidal activity, and Cmax/MIC was a poor index for arbekacin despite its concentration-dependent profile. Thus, the map would be useful for selecting the appropriate PK/PD index for an antibiotic.

References (29)

  • K. Maeda et al.

    Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs

    Drug Metab. Pharmacokinet.

    (2008)
  • R.R. Regoes et al.

    Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens

    Antimicrob. Agents Chemother.

    (2004)
  • W.A. Craig

    Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men

    Clin. Infect. Dis.

    (1998)
  • D. Czock et al.

    Pharmacokinetics and pharmacodynamics of antimicrobial drugs

    Expert Opin. Drug Metab. Toxicol.

    (2009)
  • E.I. Nielsen et al.

    Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization

    Antimicrob. Agents Chemother.

    (2011)
  • R.D. Moore et al.

    Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

    J. Infect. Dis.

    (1987)
  • A.D. Kashuba et al.

    Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria

    Antimicrob. Agents Chemother.

    (1999)
  • J.M. Hyatt et al.

    The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome

    Focus on antibacterial agents. Clin. Pharmacokinet.

    (1995)
  • P.A. Moise-Broder et al.

    Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections

    Clin. Pharmacokinet.

    (2004)
  • L.F. Shampine et al.

    The MATLAB ODE Suite

    SIAM J. Sci. Comput.

    (1997)
  • N. Sato et al.

    New concept and a theoretical consideration of the mechanism-based pharmacokinetics/pharmacodynamics (PK/PD) modeling for antimicrobial agents

    Jpn. J. Antibiot.

    (2008)
  • J.G. Den Hollander et al.

    Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo

    Antimicrob. Agents Chemother.

    (1998)
  • M. Mueller et al.

    Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC

    Antimicrob. Agents Chemother.

    (2004)
  • D.N. Gilbert

    Once-daily aminoglycoside therapy

    Antimicrob. Agents Chemother.

    (1991)
  • View full text